EZH2 and carcinoma: Reversible transition between the epithelial and mesenchymal states vertebrate carcinoma cell dissemination [10], and inhibitors of the PRC2 catalytic subunits EZH2 are currently being developed to treat several types of carcinomas as main or adjuvant therapy [11, 12].